News
NTRC announces IND approval for the TTK/PLK dual inhibitor BAL0891 in its collaboration with Swiss pharmaceutical company Basilea
Oss – Venture Challenge alumnus NTRC, specialized in discovery and development of innovative kinase inhibitors to treat cancer patients, today announces that the U.S.
ATRO Medical closes a new financing round for the Trammpolin® meniscus prosthesis
Nijmegen - Venture Challenge Alumnus ATRO Medical announces the successful closure of a €1,9 million financing round.
Venture Challenge alumnus Sirius Medical announces second closing of A-round financing to accelerate US expansion
Eindhoven, Netherlands – Sirius Medical, a leader in tumor navigation technology, announced today the closing of its second round of series A financing.
Venture Challenge Spring 2022 open for applications!
Curious what the Venture Challenge may bring you? This is what last year's alumni say about it.
Venture Challenge alumnus Nutrileads wins FI Europe Innovation Award
BeniCaros™ the proprietary immune health ingredient has won the FI Europe Innovation Award in the Health Innovation Category
Eureka Eurostars awarded to Venture Challenge Winner BIMINI Biotech
BIMINI Biotech was recently awarded a Eureka Eurostars project with the aim of targeting the growth hormone receptor for novel and personalized cancer therapeutics.
Venture Challenge alumnus CC Diagnostics appoints new CEO
CC Diagnostics is proud to announce the appointment of Ronald Vos as the companies Chief Executive Officer. Ronald brings over 30 years of busi
Venture Challenge alumnus ATRO Medical initiates clinical trial
ATRO Medical has reached an important stage in tackling post-meniscectomy knee pain with the initiation of their clinical trial "AIR2"
Venture Challenge Winner Ncardia Secures $60+ Million to Enhance and Expand Leading iPSC Offerings
Gosselies, Belgium and New York, N.Y. - Ncardia forms strategic partnership with Kiniciti to build GMP capabilities to support iPSC cell therapy platforms and human cell-based in vitro discovery services
Venture Challenge alumnus Protinhi Therapeutics selected as part of BLUE KNIGHT™ collaboration for pandemic preparedness
Nijmegen -- Protinhi Therapeutics, a Netherlands-based biotechnology company specializing in protease inhibition with the aim to combat viral infectious diseases, today announced it has been se